William Blair Estimates Amgen’s Q4 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at William Blair cut their Q4 2024 EPS estimates for Amgen in a research report issued on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the medical research company will post earnings of $5.05 per share for the quarter, down from their prior estimate of $5.12. William Blair has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.57 per share. William Blair also issued estimates for Amgen’s FY2025 earnings at $21.34 EPS.

Several other brokerages have also commented on AMGN. Citigroup decreased their target price on shares of Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. UBS Group reduced their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Leerink Partners lowered their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft reduced their price objective on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $314.91.

Amgen Price Performance

Shares of AMGN opened at $277.88 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock’s 50 day moving average is $271.91 and its two-hundred day moving average is $306.43. Amgen has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a market capitalization of $149.37 billion, a PE ratio of 35.58, a P/E/G ratio of 2.79 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the previous year, the company posted $4.96 earnings per share. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 115.24%.

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in the business. Custom Index Systems LLC bought a new position in Amgen in the fourth quarter worth about $274,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter valued at $36,000. Austin Private Wealth LLC increased its stake in shares of Amgen by 19.9% in the fourth quarter. Austin Private Wealth LLC now owns 2,854 shares of the medical research company’s stock valued at $744,000 after purchasing an additional 473 shares during the period. BTC Capital Management Inc. raised its stake in Amgen by 6.5% during the 4th quarter. BTC Capital Management Inc. now owns 6,190 shares of the medical research company’s stock valued at $1,613,000 after acquiring an additional 378 shares in the last quarter. Finally, Hamilton Point Investment Advisors LLC raised its stake in shares of Amgen by 1.5% during the fourth quarter. Hamilton Point Investment Advisors LLC now owns 35,214 shares of the medical research company’s stock valued at $9,178,000 after purchasing an additional 532 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.